PTEN regulates IGF‐1R‐mediated therapy resistance in melanoma
- 26 June 2015
- journal article
- research article
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 28 (5) , 572-589
Abstract
Summary: Inhibition of the mitogen‐activated protein kinase (MAPK) pathway is a major advance in the treatment of metastatic melanoma. However, its therapeutic success is limited by the rapid emergence of drug resistance. The insulin‐like growth factor‐1 receptor (IGF‐1R) is overexpressed in melanomas developing resistance toward the BRAFV600 inhibitor vemurafenib. Here, we show that hyperactivation of BRAF enhances IGF‐1R expression. In addition, the phosphatase activity of PTEN as well as heterocellular contact to stromal cells increases IGF‐1R expression in melanoma cells and enhances resistance to vemurafenib. Interestingly, PTEN‐negative melanoma cells escape IGF‐1R blockade by decreased expression of the receptor, implicating that only in melanoma patients with PTEN‐positive tumors treatment with IGF‐1R inhibitors would be a suitable strategy to combat therapy resistance. Our data emphasize the crosstalk and therapeutic relevance of microenvironmental and tumor cell‐autonomous mechanisms in regulating IGF‐1R expression and by this sensitivity toward targeted therapies.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (GRK1302)
- Deutsche Krebshilfe (110210)
This publication has 44 references indexed in Scilit:
- Genetic alterations of PTEN in human melanomaCellular and Molecular Life Sciences, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and ActivityCancer Cell, 2011
- Insulin-Like Growth Factor System and Sporadic Malignant MelanomaThe American Journal of Pathology, 2011
- Subtle variations in Pten dose determine cancer susceptibilityNature Genetics, 2010
- Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic MelanomaClinical Cancer Research, 2009
- Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTENOncogene, 2009
- BrafV600E cooperates with Pten loss to induce metastatic melanomaNature Genetics, 2009
- The IGF-I/IGF-I Receptor Pathway: Implications in the Pathophysiology of Thyroid CancerCurrent Medicinal Chemistry, 2005
- Mutations of the BRAF gene in human cancerNature, 2002